Co-Founder Salary at Mathaltitude BETA

Graduate Recruitment Consultant | Harmonic Finance Inc | Certified B Corp Who are we? Harmonic Finance & Operations are one of the fastest growing recruitment businesses globally and we’ve looking to expand our Boston team! As the world’s first B Corp in our space, we are the go-to search partner for start-up, scale-ups and the creative Industries seeking finance and operations talent. We take pride in our model that focuses heavily on learning & development, supporting growth of our colleagues early on in their career. We are a team of 5 in Boston, and 35 globally across 3 offices. With huge opportunities for expansion and wealth creation, we’re seeking experienced recruiters who are looking to develop into future leaders! This is a brilliant opportunity for those who want to be at the forefront of the US growth within a business that already has strong foundations and a proven track record in the UK. Led by our Founder, Charlie Walker, who has successfully founded and scaled 2 intern

Parallel Squared Technology Institute (PTI) is a non-profit research institute aiming to catalyze a leap in protein analysis technology and use it to explore new biological frontiers. PTI supports open research and educational opportunities supporting rapid career development for scientists, engineers, and mathematicians. Why? Protein dysfunctions directly cause many diseases, such as Alzheimer's disease. Yet, proteins remain understudied because of technological hurdles. How? To resolve these limitations, PTI will develop mass tags enabling a new framework for multiplexed protein analysis by mass spectrometry towards achieving 100-fold increase in throughput. Scientists at and collaborating with the institute will use these gains to directly investigate disease mechanisms and resolve problems that have proven intractable for decades. Our proof of principle technology and strategies are outlined at: parallelsq.org. New career opportunities Members of PTI will be supported with industry

Who are we? Gopinion is a small Boston based start up with the goal of bridging the communication gap between businesses and their customers. Through the Gopinion mobile app, users fill out micro-surveys (max 20 seconds), and select an instant reward from either the business they reviewed or any other business in our system. The data from these micro-surveys is collected on the individual business owner's web dashboard where they can engage with the users through our app. What stage are we? We are currently in Alpha testing. We have an app in the app store, and are currently testing a proof-of-concept in 15 locations around the Copley and Harvard Square areas. We have businesses such as Flour Bakery, Burger King, Dependable Cleaners, and the Duck Tours among others. We are in the final stages of a beta version of our product which is set to release in late September, with the Harvard University Dining Services (15 locations in Harvard Square) ready to start with us when we release our

COMPANY OVERVIEW AIRNA is a biotechnology company with a mission to transform lives, one RNA edit at a time. AIRNA is pioneering the discovery and development of RNA editing therapeutics to realize the therapeutic potential of base editing for patients with rare and common diseases. RNA editing modality is poised to lead the next generation of RNA therapeutics by bringing the precision of gene editing technology with a potent and safe medicine that can be conveniently re-dosed and manufactured. Our RESTORE+™ platform is based on groundbreaking research by academic co-founders Thorsten Stafforst (University of Tübingen) and Jin Billy Li (Stanford University), who were the first to elucidate a therapeutic approach for precise editing of RNA. AIRNA has received $90 million in Series A financing from world class venture capital firms, including Forbion and Arch Venture Partners, and is headquartered in Cambridge, MA with research operations in Tübingen, Germany. JOB DESCRIPTION: AIRNA is l

COMPANY OVERVIEW AIRNA is a biotechnology company with a mission to transform lives, one RNA edit at a time. AIRNA is pioneering the discovery and development of RNA editing therapeutics to realize the therapeutic potential of base editing for patients with rare and common diseases. RNA editing modality is poised to lead the next generation of RNA therapeutics by bringing the precision of gene editing technology with a potent and safe medicine that can be conveniently re-dosed and manufactured. Our RESTORE+™ platform is based on groundbreaking research by academic co-founders Thorsten Stafforst (University of Tübingen) and Jin Billy Li (Stanford University), who were the first to elucidate a therapeutic approach for precise editing of RNA. AIRNA has received $90 million in Series A financing from world class venture capital firms, including Forbion and Arch Venture Partners, and is headquartered in Cambridge, MA with research operations in Tübingen, Germany. JOB DESCRIPTION The Directo

Description Crumbl Cookies is hiring immediately for Closing Shift Leads to join their team! Shift leads work closely with store management to carefully manage one of our working shifts. Duties primarily revolve around the general management of your direct reports, which include, but are not limited to: providing and demonstrating task instructions, keeping attendance, and measuring key performance indicators. You will be expected to keep records and produce reports that will be used to review team performance. In order to be successful in this role, you will need to have excellent communication skills and a passion for excellence, and ensure the bakery is meeting the high standards customers and employees deserve. Previous leadership experience is a plus. Shift lead responsibilities (include but are not limited to): •Manage all the basics of running the store •Make sure employees that report to you meet performance expectations •Keep employees moving at a quick/accurate pace •Handle a

Parallel Squared Technology Institute (PTI) is a non-profit research institute aiming to catalyze a leap in protein analysis technology and use it to explore new biological frontiers. PTI supports open research and educational opportunities supporting rapid career development for scientists, engineers, and mathematicians. Why? Protein dysfunctions directly cause many diseases, such as Alzheimer's disease. Yet, proteins remain understudied because of technological hurdles. How? To resolve these limitations, PTI will develop mass tags enabling a new framework for multiplexed protein analysis by mass spectrometry towards achieving 100-fold increase in throughput. Scientists at and collaborating with the institute will use these gains to directly investigate disease mechanisms and resolve problems that have proven intractable for decades. Our proof of principle technology and strategies are outlined at: parallelsq.org. New career opportunities Members of PTI will be supported with industry

Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for CF by developing novel medicines that normalize the function of the CFTR protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (NBD1), which the company believes is central to potentially unlocking meaningful improvements in clinical outcomes and quality of life for people with CF. Leveraging over a decade of the co-founders’ extensive research on NBD1, the company is advancing a pipeline of novel small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Position Summary The Senio